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Abstract: Background: Hepatoblastoma screening in the Beckwith–Wiedemann spectrum (BWSp) is
currently based on measuring a specific serum marker alpha-fetoprotein (αFP) every three months
until the fourth birthday. Frequent blood draws can be a burden for patients and their families.
Methods: We have developed a less invasive alternative testing method based on measuring αFPs
from dried blood spots (DBS). The method was validated with 259 simultaneous plasma and DBS
αFP measurements in 171 children (132 controls and 39 patients with BWSp). Results: The DBS and
plasma measurements overlapped across the wide range of αFP concentrations independent of patient
age (p < 0.0001), demonstrating the utility of this method for longitudinal monitoring. Occasional
differences between measurements by the two techniques fell within standard laboratory error and
would not alter clinical management. Conclusions: This novel method shows consistent overlap
with the traditional blood draws, thereby demonstrating its utility for hepatoblastoma screening in
this setting and alleviating the burden of frequent blood draws. This also may help increase patient
compliance and reduce costs of health care screening. The DBS-based method for the measurement of
cancer biomarkers may also be applied to several other chronic diseases with increased risks of
αFP-producing liver tumors.
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1. Introduction
The Beckwith–Wiedemann spectrum (BWSp) consists of the variable association of macroglossia,
abdominal wall defects, organomegaly, ear pits/creases, facial nevus simplex, hyperinsulinemic
hypoglycemia, lateralized overgrowth, and embryonal tumor predisposition [1–3]. BWSp includes
the classical Beckwith–Wiedemann syndrome (BWS, OMIM #130650), the most common overgrowth
and cancer predisposition disorder (1:10,500 live births) [4], and more subtle presentations with an
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11p15.5 molecular anomaly, including Isolated Lateralized Overgrowth (ILO, OMIM #235000) [5].
The BWSp embryonal tumor predisposition in childhood includes an increased risk of developing
hepatoblastoma (HB), which occurs in up to 3.5% of patients depending on the specific genetic
anomaly [6,7]. HB typically occurs before 30 months of age with a peak of incidence at six months [8,9],
and BWS represents the most relevant risk factor for HB, with a relative risk of 2280 times greater than
in the general population [10]. The molecular subgroups of BWS patients with the highest risk for HB
are those with paternal uniparental disomy (UPD) of chromosome 11 or genome-wide UPD [11–13].
Moreover, HB is the most common tumor diagnosed in BWSp children with the loss of methylation
at imprinting control region 2, the molecular subgroup representing approximately 50% of BWSp
patients [14].
HB usually grows rapidly; therefore, survival and prognosis are highly dependent on early
diagnosis [8,9,15]. More than 95% of HB secrete the highly sensitive and specific tumor marker
alpha-fetoprotein (αFP) [9,15], and measuring αFPs are used in diagnosis, follow-up, and relapse
detection. BWSp patients are monitored for HB with αFPs every three months from birth to the fourth
birthday [16–19]. Screening provides the opportunity for early detection and at earlier stages of the
diagnosis, potentially allowing for less toxic therapies [20,21].
However, αFP screening in this population has been controversial for a number of
reasons [6,7,14,22–24]. First, the variability in the physiologic decrease of normal serum αFP levels
(from 105 U/mL magnitude at birth to concentrations steadily <10 U/mL by the age of 12–24 months)
leads to challenges in the interpretation of αFP levels in early infancy [25,26]. Moreover, normal
αFP values in BWS patients in the first year of life tend to be elevated compared with normal
pediatric values [27]. Age-corrected reference values should be employed [25,26], and αFP trends,
rather than reliance of the actual value compared to non-BWS norms, is a more accurate screening
strategy [16,23,28].
Second, some health care providers consider the incidence of HB too low to warrant specific
screening [2]: While recently the American Association for Cancer Research (AACR) Childhood
Cancer Predisposition Workshop adopted a 1% risk threshold for surveillance and recommended αFP
screening for all cases of BWSp [29], a consensus statement from the European Network of Human
Congenital Imprinting Disorders (EUCID) judged a 5% threshold to be more appropriate for European
healthcare systems and did not recommend αFP screening in these patients [2].
Lastly, the frequent blood draw schedule in early infancy is perceived as invasive, represents a
burden for some children and families, and may cause compliance issues [22,23]. However, parents
report being comforted and reassured by the screening [30]. For this reason, in a previous report
we demonstrated the technical feasibility of αFP determination using dried capillary blood spots
(DBS) [31]. Here we demonstrate the utility of DBS in parallel to the currently accepted practice of
venous αFP sampling in a range of BWSp patients and normal controls. The method described
in our previous report was introduced as a clinical practice pilot program in our institution and
compared in parallel to the standard laboratory method. In this report, we describe our experience in
the longitudinal monitoring of BWSp by the novel method, further supporting its utility in routine
clinical practice.
2. Results
Measurements on plasma and DBS were closely correlated (r2 = 0.999, p < 0.001, Figure 1).
Raw measurement data are provided in Supplementary Table S1. The αFP measurements by the
two methods showed consistency and largely overlapped across the wide range of physiological
concentrations of the tumor marker (0.3–97,198.0 U/mL in plasma and from 0.1 to 97,889.0 U/mL
on DBS).
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Figure 1. Correlation between α-fetoprotein (αPF) measured on plasma and on dried blood spot 
(DBS) (r2 = 0.999, p < 0.001).  
In 202 cases, both methods measured αFP ≤10 U/mL, whereas in 51 cases, both measurements 
were >10 U/mL. In five cases, αFP was >10 U/mL in plasma and ≤10 U/mL on DBS: Patient 3 with 
11.4 U/mL on plasma and 9.8 U/mL on DBS, Patient 4 with 11.5 U/mL on plasma and 4.1 U/mL on 
DBS, and Patient 5 with 12.0 U/mL on plasma and 8.3 U/mL on DBS. In one case, serum αFP was ≤10 
U/mL (9.9 U/mL) and >10 U/mL on DBS (14.3 U/mL). All the paired measurements show differences 
between serum and DBS measurements within the coefficient of variation (CV%). Twenty-six 
patients and 20 controls had more than one αFP measurement; 22 patients and 123 controls had 1 
paired measurement.  
Of the 26 patients with a longitudinal assessment, 12 patients had αFP measurements >10 
U/mL: Their αFP trend over time is displayed in Figure 2 to highlight the concordance between the 
two methods. The remaining 14 patients were assessed longitudinally, and all had concordant 
DBS-plasma αFP <10 U/mL over time (not shown as values under 10 U/mL are considered within 
normal range). Of the 22 patients tested with a single paired measurement, 19 had concordant 
DBS-plasma αFP values <10 U/mL and three had values >10 U/mL. In the latter group, Patient 29 
showed 225.0 U/mL in plasma and 212.0 U/mL on DBS, Patient 30 had 609.0 U/mL in plasma and 
610.5 U/mL on DBS, and Patient 37 had 187.1 U/mL in plasma and 168.0 U/mL on DBS. The patient 
diagnosed with non-syndromic HB, a female aged 31 months, had an αFP of 583.5 U/mL measured 
by the traditional method and 601.0 U/mL on DBS. 
Figure 1. Correlation between α-fetoprotein (αPF) measured on plasma and on dried blood spot (DBS)
(r2 = 0.999, p < 0.001).
In 202 cases, both methods measured αFP ≤10 U/mL, whereas in 51 cases, both measurements
were >10 U/mL. In five cases, αFP was >10 U/mL in plasma and ≤10 U/mL on DBS: Patient 3 with
11.4 U/mL on plasma and 9.8 U/mL on DBS, Patient 4 with 11.5 U/mL on plasma and 4.1 U/mL
on DBS, and Patient 5 with 12.0 U/mL on plasma and 8.3 U/mL on DBS. In one case, serum αF
was ≤10 U/mL (9.9 U/mL) and >10 U/mL on DBS (14.3 U/mL). All the paired measurements
show differences between serum and DBS measurements within the coefficient of variation (CV%).
Twenty-six patients and 20 controls had ore than one αFP easurement; 22 patients and 123 controls
had 1 paired measure ent.
Of the 26 patients with a longitudinal assessment, 12 patients had αFP measurements >10 U/mL:
Their αFP trend over time is displayed in Figure 2 to highlight the concordance between the two
methods. The rem ining 14 patients were assessed longitudinally, a d all had concordant DBS-plasma
αFP <10 U/mL over time (not shown as values under 10 U/mL are considered within normal range).
Of the 22 patients tested with a single paired measurement, 19 had concordant DBS-plasma αFP values
<10 U/mL and three had values >10 U/mL. In the latter group, Patient 29 showed 225.0 U/mL in
plasma and 212.0 U/mL on DBS, Patient 30 had 609.0 U/mL in plasma and 610.5 U/mL on DBS,
and Patient 37 had 187.1 U/mL in plasma and 168.0 U/mL on DBS. The patient diagnosed with
non-syndromic HB, a female aged 31 months, had an αFP of 583.5 U/mL measured by the traditional
method and 601.0 U/mL on DBS.
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Figure 2. The longitudinal evaluation of alpha-fetoprotein (αFP) plasmatic concentration on dried 
blood spots (DBS, closed circles) overlapped that on standard laboratory method (open circles) in the 
12 patients affected by cancer-predisposition syndromes with αFP concentrations >10 U/mL.  
3. Discussion 
In this work, we demonstrate the feasibility of HB screening in overgrowth-cancer 
predisposition syndromes using DBS for αFP measurements. DBS, a novel method to measure αFP 
concentration showed consistent overlap with the traditional venous sampling method, showing 
reliability in the clinical setting of a tumor screening program. In the first two years of life—those in 
which the likelihood of developing HB is commonly higher in such conditions [9]—αFP 
concentrations decrease rapidly from a 106–105 to a <10 U/mL magnitude, with almost unpredictable 
and variable timing, making interpretations challenging. Although age-specific and gestational 
age-corrected normal αFP concentrations values are available [32], HB screening relies mostly on the 
longitudinal observation of repeated measurements of αFP concentrations rather than on the 
detection of a single measurement [28,29]. The DBS measurements overlapped the serum 
measurements across a wide range of physiologic concentrations and ages, demonstrating the utility 
of our methodology for longitudinal monitoring in both newborns and toddlers. Moreover, the 
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3. Discussion
In this work, we demonstrate the feasibility of HB screening in overgrowth-cancer predisposition
syndromes using DBS for αFP measurements. DBS, a novel method to measure αFP concentration
showed consistent overlap with the traditional venous sampling method, showing reliability in
the clinical setting of a tumor screening program. In the first two years of life—those in which
the likelihood of developing HB is commonly higher in such conditions [9]—αFP concentrations
decrease rapidly from a 106–105 to a <10 U/mL magnitude, with almost unpredictable and variable
timing, making interpretations challenging. Although age-specific and gestational age-corrected
normal αFP concentrations values are available [32], HB screening relies mostly on the longitudinal
observation of repeated measurements of αFP concentrations rather than on the detection of a single
measurement [28,29]. The DBS measurements overlapped the serum measurements across a wide
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range of physiologic concentrations and ages, demonstrating the utility of our methodology for
longitudinal monitoring in both newborns and toddlers. Moreover, the range of measurements
includes a 105 magnitude often observed in prematurity [32], which is common in the BWSp [33].
After the physiological decrease of αFP serum concentrations, a cutoff of >10 U/mL is commonly
used to define normal values after 2 years of age. The measurement provided by the traditional
and novel methods consistently matched across this diagnostic threshold, allowing, therefore, the
determination of normal screens compared to abnormal screening tests. The few cases with discordant
plasma and DBS measurements showed very tight fluctuations across the 10 U/mL threshold within
the acceptable error range for these tests, and clinical management was not altered by these fluctuations.
Additionally, our patient who was ultimately diagnosed with a non-syndromic HB, showed that
αFP levels determined by the two methods were highly consistent in the setting of a tumor diagnosis
as well. Hence, we propose using DBS for HB screening and for patients presenting abnormal results
suggesting a tumor diagnosis; further investigation with both conventional venous αFP testing and
imaging studies should be used to confirm or exclude a HB diagnosis. Finally, the DBS technique
alleviates the burden of frequent blood draws and is simple, efficient and low-cost, thus making the
routine measurement of αFP more practical. These aspects are crucial to improve patients’ compliance
with tumor surveillance recommendations for cancer predisposition syndromes. It has recently been
shown that accurate knowledge about cancer risk and screening in the BWSp context decreases parents’
worries about tumor development [30] and that the DBS method may also decrease children’s anxiety
related to HB screening. The DBS method is cheaper in terms of storage, transport, and handling even
compared to other minimally invasive methods (i.e., finger poke in microtainer tube) that require that
the samples remain in a liquid state [34]. DBS home sampling is associated with a reduction in costs
both from a healthcare and from a societal perspective with patient costs abated nearly to zero and
with a relevant decrease in costs related to the loss of productivity [35].
Other potential applications of the DBS method may come from this work and include screening of
other conditions with increased risk of hepatocarcinoma or other αFP-secreting tumors as well as
follow-up of patients treated for liver tumors. As screening for hepatocarcinoma in cirrhotic patients
by repeated serum αFP measurement is feasible [36] and results in increased survival rates [28,37],
monitoring in cirrhotic patients by DBS may represent a specific example of future applications.
4. Materials and Methods
4.1. Patients
Overall, 259 simultaneous plasma and DBS αFP measurements were performed in 171 children
(mean age 38.7 ± 59.2 months, range 0–7.3 years, 88 males, 83 females). Of these, 116 paired
measurements have been performed in 48 patients with syndromes with increased risk of HB for
tumor screening (range 0–60 months): 39 were affected by BWSp/ILO (23 molecularly confirmed,
16 diagnosed clinically with negative molecular tests), 3 had macrocephaly-capillary malformation
syndrome, 5 had undiagnosed likely syndromic overgrowth disorders, and one girl had an isolated HB.
Of these, 31 measurements from 31 patients were previously reported in our preliminary report [31].
The remaining 143 paired measurements were performed in 123 children as controls: 27 were healthy
children and 96 underwent blood tests for suspected conditions with no effect on plasmatic αFP
concentration (20 suspected or well compensated thyroid disorders, 35 with recently healed infections,
12 serum lipids screening, 13 affected by phenylketonuria, 10 suspected iron deficient anemia, and
6 suspected precocious puberty). Besides studying the potential utility of the DBS method for
longitudinal monitoring, we applied the novel method to patients admitted for suspected abdominal
tumors. Twenty-three paired measurements were therefore performed in patients referred to our
Division of Pediatric Oncology for suspected neoplasms and who had αFP measurement with the
aim to identify potential αFP producing tumors. Among the last cases, the suspected diagnosis of
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neoplasm was excluded after the tests (including αFP and appropriate imaging) except for one female
who was ultimately diagnosed with non-syndromic HB.
4.2. Study and Screening Protocol
Informed consent was obtained from parents using a study protocol approved by the Institutional
Review Board of our University Hospital (IRB number CS/156/2014 Città della Salute e della Scienza di
Torino, University of Torino, Italy). Our protocol for HB screening in overgrowth-cancer predisposition
syndromes is consistent with that proposed by the American Association for Cancer Research [29]
and is based on 3 months’ abdominal ultrasound and simultaneous αFP measurements by standard
laboratory methodology from birth up to the fourth birthday [17]. A negative αFP test is defined as an
αFP measurement less than 10 U/mL (1 U/mL = 1.21 ng/mL) or declining with respect to previous
measurement. The individual value is interpreted in the context of the αFP trend over time, with
an expectation of declining values through infancy. In case of concentrations >10 U/mL, the results
need to be interpreted on the basis of normal BWS values (which tend to be elevated over the first
years of life compared with normal pediatric values), with age-specific and gestational age-corrected
reference values provided in the literature [25] and with previous measurements performed in the
same patient, if available. If the concentrations are less than the previous ones, then we consider the
test negative and register the absolute value in order to perform subsequent comparisons. If we detect
an αFP greater than the previous one, the test is referred to as positive, recent imaging is re-evaluated,
and the patient is recalled for subsequent αFP remeasurements after a 6-week interval for rises greater
than 50–100 U/mL [29]. In cases of significantly larger increases (greater than 1000 U/mL) or with
further increase at the 6 weeks αFP remeasurement, second-step medical investigations are proposed
(targeted liver US or MRI) [29].
4.3. Laboratory Assays
Paired αFP measurements were simultaneously performed on blood, obtained by venipuncture,
and DBS, collected by heel-stick or by spotting single blood drops from a syringe directly onto
standard filter paper employed for newborn screening. The DBS specimens were dried at room
temperature, routinely stored in plastic bags at 4 ◦C and analyzed employing a 3.2 mm-diameter
spotted filter paper punch containing approximately 3.4 µL of adsorbed blood. The serum αFP
measurement kit (AutoDELFIA hAFP, Perkin Elmer, Waltham, Massachusetts) adapted to the DBS
technique has been employed, as previously described [31]. The intra-assay CV% was evaluated for
quality controls: For low concentrations (~10 U/mL), the CV%s were 3.02% for the plasma assay and
4.11% for the DBS one; for high concentrations quality controls (~70 U/mL), the CV%s were 3.05% and
3.22%, respectively.
4.4. Statistics
Data were analysed by GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA, USA).
Data distribution was assessed by the Shapiro–Wilk test and correlations tested by Pearson or Sperman
methods, accordingly.
5. Conclusions
In conclusion, in this study we demonstrate that screening children with overgrowth disorders
with HB predispositions can be performed by a novel simple method, which measures αPF on DBS.
This novel technique may lead to increased adherence and reduced anxiety and cost.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/1/86/s1,
Table S1: Raw data of the paired measurements of alpha-fetoprotein (αFP) with the traditional and dried blood
spot (DBS) methods.
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